Your browser doesn't support javascript.
loading
Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.
Hashimoto, Yoshinori; Ito, Tomoki; Tanaka, Yasuhiro; Nakaya, Aya; Fujita, Shinya; Satake, Atsushi; Nakanishi, Takahisa; Konishi, Akiko; Hotta, Masaaki; Yoshimura, Hideaki; Ishii, Kazuyoshi; Hashimoto, Akiko; Kondo, Toshinori; Omura, Hiromi; Shinzato, Isaku; Tanaka, Takayuki; Nomura, Shosaku.
Affiliation
  • Hashimoto Y; Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Tottori, Japan.
  • Ito T; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan. itot@hirakata.kmu.ac.jp.
  • Tanaka Y; Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Hyogo, Japan.
  • Nakaya A; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Fujita S; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Satake A; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Nakanishi T; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Konishi A; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Hotta M; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Yoshimura H; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Ishii K; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
  • Hashimoto A; Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Hyogo, Japan.
  • Kondo T; Department of Hematology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
  • Omura H; Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Tottori, Japan.
  • Shinzato I; Department of Hematology and Clinical Immunology, Kobe City Nishi-Kobe Medical Center, Kobe, Hyogo, Japan.
  • Tanaka T; Department of Hematology, Tottori Prefectural Central Hospital, Tottori, Tottori, Japan.
  • Nomura S; First Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-City, Osaka, 573-1010, Japan.
Int J Hematol ; 112(1): 33-40, 2020 Jul.
Article in En | MEDLINE | ID: mdl-32328973
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Platelet Aggregation Inhibitors / Thrombocythemia, Essential Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2020 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Platelet Aggregation Inhibitors / Thrombocythemia, Essential Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2020 Document type: Article Affiliation country: